Cargando…

Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential

Mitochondrial dysfunction is strongly implicated in the etiology of idiopathic and genetic Parkinson’s disease (PD). However, strategies aimed at ameliorating mitochondrial dysfunction, including antioxidants, antidiabetic drugs, and iron chelators, have failed in disease-modification clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henrich, Martin T., Oertel, Wolfgang H., Surmeier, D. James, Geibl, Fanni F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640762/ https://www.ncbi.nlm.nih.gov/pubmed/37951933 http://dx.doi.org/10.1186/s13024-023-00676-7

Ejemplares similares

The roles of connectivity and neuronal phenotype in determining the pattern of α-synuclein pathology in Parkinson's disease
por: Henderson, Michael X., et al.
Publicado: (2022)

Determinants of seeding and spreading of α-synuclein pathology in the brain
por: Henrich, Martin T., et al.
Publicado: (2020)

Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson’s disease
por: Matschke, Lina A., et al.
Publicado: (2022)

A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson’s disease-like pathology in neurons and glia
por: Henrich, Martin Timo, et al.
Publicado: (2018)

Mitochondrial Respiratory Chain Dysfunction—A Hallmark Pathology of Idiopathic Parkinson’s Disease?
por: Flønes, Irene H., et al.
Publicado: (2022)

Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder
por: Janzen, Annette, et al.
Publicado: (2022)

Calcium, Bioenergetics, and Parkinson’s Disease
por: Zampese, Enrico, et al.
Publicado: (2020)

Mitochondrial Dysfunction as a Hallmark of Environmental Injury
por: Duarte-Hospital, Carolina, et al.
Publicado: (2021)

Mitochondrial Dysfunction and Parkinson’s Disease—Near-Infrared Photobiomodulation as a Potential Therapeutic Strategy
por: Foo, Aaron Song Chuan, et al.
Publicado: (2020)

Gene Therapeutic Approaches for the Treatment of Mitochondrial Dysfunction in Parkinson’s Disease
por: Prasuhn, Jannik, et al.
Publicado: (2021)

Mitochondrial dysfunction-targeting therapeutics of natural products in Parkinson’s disease
por: He, Ting, et al.
Publicado: (2023)

Mitochondrial Dysfunction in Parkinson's Disease
por: Keane, P. C., et al.
Publicado: (2011)

Mitochondrial Dysfunction in Parkinson's Disease
por: Moon, Hyo Eun, et al.
Publicado: (2015)

Mitochondrial dysfunction in Parkinson’s disease
por: Hu, Qingsong, et al.
Publicado: (2016)

Striatal synaptic adaptations in Parkinson’s disease
por: Shen, Weixing, et al.
Publicado: (2022)

Gastrointestinal Dysfunction in Parkinson’s Disease: Current and Potential Therapeutics
por: Han, Myat Noe, et al.
Publicado: (2022)

Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives
por: Park, Jin-Sung, et al.
Publicado: (2018)

Hallmarks and Molecular Tools for the Study of Mitophagy in Parkinson’s Disease
por: Goiran, Thomas, et al.
Publicado: (2022)

Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson’s Disease
por: Tryphena, Kamatham Pushpa, et al.
Publicado: (2023)

Recent advances in treating Parkinson’s disease
por: Oertel, Wolfgang H.
Publicado: (2017)

Membrane potential and delta pH dependency of reverse electron transport-associated hydrogen peroxide production in brain and heart mitochondria
por: Komlódi, Tímea, et al.
Publicado: (2018)

Mitochondrial Dysfunction in Parkinson’s Disease: Focus on Mitochondrial DNA
por: Buneeva, Olga, et al.
Publicado: (2020)

Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson’s disease
por: Goldberg, Joshua A., et al.
Publicado: (2012)

Mitochondrial hyperactivity as a potential therapeutic target in Parkinson’s disease
por: Mor, Danielle E., et al.
Publicado: (2020)

Reactive Oxygen Species: A Key Hallmark of Cardiovascular Disease
por: Panth, Nisha, et al.
Publicado: (2016)

Animal models of Parkinson’s disease: bridging the gap between disease hallmarks and research questions
por: Dovonou, Axelle, et al.
Publicado: (2023)

Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease
por: Hoekstra, Jake G, et al.
Publicado: (2011)

Mitochondrial Dysfunction in Parkinson's Disease: Pathogenesis and Neuroprotection
por: Mounsey, Ross B., et al.
Publicado: (2010)

The genetic architecture of mitochondrial dysfunction in Parkinson’s disease
por: Larsen, S. B., et al.
Publicado: (2018)

Mitochondrial Dysfunction in Parkinson’s Disease—Cause or Consequence?
por: Chen, Chun, et al.
Publicado: (2019)

Mitochondrial dysfunction is a key pathological driver of early stage Parkinson’s
por: Toomey, Christina E., et al.
Publicado: (2022)

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic Implications
por: Zheng, Wei, et al.
Publicado: (2022)

Rethinking the network determinants of motor disability in Parkinson’s disease
por: Surmeier, Dalton James, et al.
Publicado: (2023)

Delayed Spine Pruning of Direct Pathway Spiny Projection Neurons in a Mouse Model of Parkinson’s Disease
por: Graves, Steven M., et al.
Publicado: (2019)

Brain Mitochondrial Dysfunction in Aging, Neurodegeneration, and Parkinson's Disease
por: Navarro, Ana, et al.
Publicado: (2010)

Synergistic Effect of Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease
por: Guerra, Flora, et al.
Publicado: (2019)

Mitochondrial Dysfunction in Astrocytes: A Role in Parkinson’s Disease?
por: Bantle, Collin M., et al.
Publicado: (2021)

Integrating the Hallmarks of Aging Throughout the Tree of Life: A Focus on Mitochondrial Dysfunction
por: van der Rijt, Sanne, et al.
Publicado: (2020)

Pathway‐Specific Remodeling of Thalamostriatal Synapses in a Mouse Model of Parkinson's Disease
por: Tanimura, Asami, et al.
Publicado: (2022)

The mitochondrial calcium uniporter: a new therapeutic target for Parkinson’s disease-related cardiac dysfunctions?
por: Scorza, Fúlvio Alexandre, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fv6irff9jquq5p95hsn9mfn9oe